[BIO USA] Alteogen CEO Taeyeon Jeon Expects Record-Breaking Technology Exports This Year
Expansion into New Areas Including ADC and RNA
Patent Uncertainties Resolved
1.5 Trillion Won in MSD Milestones Remaining
Royalties to Ramp Up Within Three Years
"This year, we expect to achieve the highest performance in both the number and scale of contracts," he said.
On June 23 (local time), Taeyeon Jeon, CEO of Alteogen, made these remarks while speaking with reporters at the 2026 Bio International Convention (BIO USA) in San Diego, USA. Regarding one of the deals currently under negotiation, CEO Jeon said, "This could become the largest contract that Alteogen has ever signed." He added, "Recently, more companies are seeking to contract for multiple items at once rather than a single product," and explained, "Among them, there is one company that wants to sign for a very large number of products simultaneously, so the discussions have progressed significantly."
Taeyeon Jeon, CEO of Alteogen, explained the possibility of additional technology transfers on the 23rd (local time) at the 2026 BIO International Convention (BIO USA) held in San Diego, USA. Photo by Minjae Kwak
View original imageThe company is currently conducting material transfer agreements (MTAs) with about 10 companies. There is also a growing demand from existing partners to expand their pipelines. CEO Jeon stated, "Some of the companies we have already signed with are requesting to add another pipeline," and added, "Since the pipeline is being added through a contract amendment, it is essentially the same as a new deal."
The therapeutic areas where Alteogen's human hyaluronidase-based platform 'ALT-B4' is being applied are also expanding rapidly. ALT-B4 is a technology that converts existing intravenous (IV) therapies to subcutaneous (SC) formulations, thereby reducing administration time and improving patient convenience. CEO Jeon emphasized, "We have already signed contracts for ADC applications, and collaborations are also being discussed in the RNA field," and noted, "We are seeing positive results even in areas that we have not previously explored."
With regard to ADC applications, the company also released internal animal study results. When ALT-B4 and ADC were administered together, skin toxicity at the injection site was significantly reduced, and immune cell damage also decreased markedly. CEO Jeon said, "We have confirmed that it not only improves convenience of administration but also adds clinical benefits." There had been some skepticism in the industry that converting ADCs to SC formulations would be difficult, but the company has effectively refuted this. The timeline for commercializing SC conversion is also becoming clearer. Following the launch of Keytruda SC last year, Sanofi's Dupixent SC, Daiichi Sankyo's Enhertu SC, and AstraZeneca's Imfinzi SC are expected to be released sequentially between 2029 and 2030.
Many of the uncertainties regarding patents have also been resolved. Merck (MSD) filed a post-grant review (PGR) against Halozyme's MDASE patent, and three consecutive decisions have been made to invalidate the patent. In May of this year, the inter partes review (IPR) seeking to invalidate Alteogen's own process patent was also dismissed. CEO Jeon said, "As trust in the patents has increased, the responses from our partners have changed as well," and explained, "In the past, they would send Excel files with dozens of questions about each of Halozyme's patent claims, but now they only ask for updates on the litigation process."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CEO Jeon also expressed confidence about the revenue structure. He said, "There is a minimum amount that Alteogen requires, and if the milestones do not reach that level, we adjust by focusing on royalties," adding, "We never take a loss." Regarding the contract with MSD, he explained, "There is still 1.5 trillion won remaining in milestones, and it looks like they will be achieved soon," and predicted, "About three years after the milestones, royalties will begin in earnest."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.